Business
ShareSoc Growth Company Seminar
ShareSoc Growth Company Seminar.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 9152G Avacta Group PLC 05 June 2017 \n\n5 June 2017\n \nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\n \nAvacta to Present at ShareSoc Growth Company Seminar\n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at the ShareSoc Growth Company Seminar on Wednesday 14th June in London at Capita Asset Services, 40 Dukes Place, London EC3A 7NH.\n \nThe evening event, which begins with registration at 17:00, provides an opportunity for investors to hear about the Company's Affimer® technology, its development plans and to discuss these with Alastair and with Dr Amrik Basran, Avacta's Chief Scientific Officer. \n \n \nENDS\n \n \nNOTES\n \nFor further information from Avacta Group plc, please contact:\n \n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\n \n\n\nTel: +44 (0) 844 414 0452\nwww.avacta.com \n\n\n\n\nfinnCap Ltd\nGeoff Nash / Giles Rolls - Nominated Adviser\nTim Redfern / Alice Lane - Corporate Broking\n \nWG Partners\nNigel Birks / Nigel Barnes\nDavid Wilson / Claes Spang\n\n\nTel: +44 (0) 207 220 0500\nwww.finncap.com\n \n \nTel: +44 (0) 203 705 9318\nTel: +44 (0) 203 705 9217\nwww.wgpartners.co.uk\n \n\n\n\n\nZyme Communications (Trade and Regional Media)\nKatie Odgaard\n \nFTI Consulting (Financial Media and IR)\nSimon Conway / Natalie Garland-Collins\n\n\nTel: +44 (0)7787 502 947\[email protected] \n \nTel: +44 (0) 203 727 1000\[email protected] \n\n\n\n\n \n \nAbout Avacta Group plc (www.avacta.com)\nAvacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.\n \nAffimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small p...